Early Life Antibiotic Exposure Is Not Associated with Growth in Young Children of Vellore, India - 24/10/15
, Daniel J. Westreich, PhD 1, Linda S. Adair, PhD 2, Sylvia Becker-Dreps, MD 3, Robert S. Sandler, MD 1, 4, Rajiv Sarkar, PhD 5, Deepthi Kattula, BDS, MSc 5, Honorine D. Ward, MBBS 5, 6, Steven Meshnick, MD, PhD 1, Gagandeep Kang, MD, PhD 5Abstract |
Objectives |
To estimate the effects of antibiotic exposures in the first 6 months of life on short- and long-term growth.
Study design |
In a prospective observational cohort study of 497 children from Vellore, India, we estimated short-term effects of antibiotics during the first 6 months using longitudinal general linear regression to model weight-for-age, height-for-age, and weight-for-height z-scores in monthly intervals. To estimate long-term effects, we modeled growth from 6 months to 3 years as a function of antibiotic use in the first 6 months. We also estimated the effects of antibiotics on the monthly relative risks of underweight, stunting, and wasting in the first 6 months and to 3 years.
Results |
Underweight, stunting, and wasting were common in this population: 31%, 32%, and 15% on average after 6 months of age, respectively. There was no association between antibiotic exposures before 6 months and growth during that period. From 6 months to 3 years, adjusted absolute differences in weight and height were small (approximately −100 g and no more than −2 mm overall, respectively) and not statistically significant.
Conclusions |
Antibiotic exposures early in life were not associated with increased or decreased growth. The combination of malnutrition and recurrent illness likely complicate the relationship between antibiotic exposures and growth among children in low and middle-income countries.
Le texte complet de cet article est disponible en PDF.Keyword : GEE, HAZ, LMIC, WAZ, WHO, WHZ
Plan
| Supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH; 5-R01-AI072222 [to H.W.], 5-T32-AI070114-08 [to E.R.], D43-TW007392 [to D.K.], and 1-R56-AI108515 [to S.B.-D.]) and the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Office of the Director of the National Institutes of Health (NICHD; DP2-HD084070 [to D.W.]). S.B.-D. has held investigator-initiated research grants with Pfizer, Inc and Merck for research studies completely unrelated to the submitted work. D.W. engages in ad hoc consulting on epidemiologic methods for NIH/NICHD. The other authors declare no conflicts of interest. |
Vol 167 - N° 5
P. 1096 - novembre 2015 Retour au numéro
Article précédent
- Comparing the Use of Centers for Disease Control and Prevention and World Health Organization Growth Charts in Children with Cystic Fibrosis through 2 Years of Age
- Zhumin Zhang, Suzanne M. Shoff, HuiChuan J. Lai
- Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome
- Daniël R. Hoekman, Juliette M.T.M. Rutten, Arine M. Vlieger, Marc A. Benninga, Marcel G.W. Dijkgraaf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?